Zymeworks to Present at Raymond James Life Sciences and MedTech Conference

VANCOUVER, British Columbia–(BUSINESS WIRE)–Zymeworks Inc. (NYSE/TSX: ZYME), a clinical-stage biopharmaceutical
company developing multifunctional biotherapeutics, today announced that
management will present at the upcoming Raymond James Life Sciences and
MedTech Conference taking place June 18-19, 2019 in New York, NY.

The Company’s presentation will be on Wednesday, June 19, 2019 at 11:30
a.m. ET.

About Zymeworks Inc.

Zymeworks is a clinical-stage biopharmaceutical company dedicated to the
development of next-generation multifunctional biotherapeutics. The
Company’s suite of therapeutic platforms and its fully integrated drug
development engine enable precise engineering of highly
differentiated product candidates. Zymeworks’ lead clinical candidate,
ZW25, is a novel Azymetric™ bispecific antibody currently in Phase 2
clinical development. The Company’s second clinical candidate, ZW49, is
a bispecific antibody-drug conjugate currently in Phase 1 clinical
development and combines the unique design and antibody framework of
ZW25 with Zymeworks’ proprietary ZymeLink™ cytotoxic payload. Zymeworks
is also advancing a deep preclinical pipeline in immuno-oncology and
other therapeutic areas. In addition, its therapeutic platforms are
being leveraged through strategic partnerships with nine
biopharmaceutical companies. For more information, visit www.zymeworks.com.


Zymeworks Inc.

Ryan Dercho, Ph.D.
(604) 678-1388

Tiffany Tolmie
(604) 678-1388

Media Inquiries:
Angela Bitting
(925) 202-6211